HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cyclin G1

A cyclin G subtype that is constitutively expressed throughout the cell cycle. Cyclin G1 is considered a major transcriptional target of TUMOR SUPPRESSOR PROTEIN P53 and is highly induced in response to DNA damage.
Networked: 71 relevant articles (5 outcomes, 21 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Gordon, Erlinda M: 8 articles (03/2019 - 08/2002)
2. Hall, Frederick L: 8 articles (03/2019 - 08/2002)
3. Chawla, Sant P: 5 articles (03/2019 - 09/2009)
4. Chen, Z H: 4 articles (07/2001 - 07/2000)
5. Gordon, E M: 4 articles (07/2001 - 07/2000)
6. Hall, F L: 4 articles (07/2001 - 07/2000)
7. Bolondi, Luigi: 3 articles (11/2014 - 07/2007)
8. Fornari, Francesca: 3 articles (11/2014 - 07/2007)
9. Giovannini, Catia: 3 articles (11/2014 - 07/2007)
10. Gramantieri, Laura: 3 articles (11/2014 - 07/2007)

Related Diseases

1. Neoplasms (Cancer)
05/01/2010 - "This review describes the major milestones in the clinical development of Rexin-G: from the molecular cloning and characterization of the human cyclin G1 proto-oncogene in 1994, to the design of the first knockout constructs and genetic engineering of the targeted delivery system from 1995 to 1997, through the initial proofs-of-concept, molecular pharmacology and toxicology studies of Rexin-G in preclinical cancer models from 1997 to 2001, to the pioneering clinical studies in humans from 2002 to 2004, which--together with the advancements in bioprocess development of high-potency clinical grade vectors circa 2005 - 2006--led to the accelerated approval of Rexin-G for all solid tumors by the Philippine FDA in 2007 and the rapid progression of clinical studies from 2007 to 2009 to the cusp of pivotal Phase III trials in the US. "
05/01/2015 - "Consistently, p53 target genes including p21, cyclin G1 and Msh2 are reduced in Caspase-2-deficient tumors. "
05/01/2010 - "Rexin-G, a tumor-targeted retrovector bearing a cytocidal cyclin G1 construct, is the first targeted gene therapy vector to gain fast track designation and orphan drug priorities for multiple cancer indications in the US. "
07/15/2009 - "We have previously shown that miR-122 can regulate the expression of cyclin G1, whose high levels have been reported in several human cancers. "
04/01/2003 - "In conclusion, our data suggest that the decreased tumor susceptibility after loss of cyclin G1 function is caused by the increased tumor suppressor action of p53."
2. Osteosarcoma (Osteogenic Sarcoma)
3. Neointima
4. Hepatocellular Carcinoma (Hepatoma)
5. Colorectal Neoplasms (Colorectal Cancer)

Related Drugs and Biologics

1. Carcinogens
2. Cyclin D1
3. Proteins (Proteins, Gene)
4. Progesterone
5. MicroRNAs (MicroRNA)
6. Proliferating Cell Nuclear Antigen (PCNA)
7. Cyclin-Dependent Kinases (cdk Proteins)
8. Cell Cycle Proteins
9. Ellagic Acid
10. Collagen

Related Therapies and Procedures

1. Intravenous Infusions
2. Drug Therapy (Chemotherapy)
3. Therapeutics
4. Axotomy
5. Injections